Positive AZUR-1 data de-risks a new indication for Jemperli and supports accelerated regulatory filings. Traders should watch for FDA acceptance of a supplemental BLA and potential approval timeline (likely 2027). The data also strengthens GSK's immuno-oncology positioning. Monitor for detailed results at a future scientific congress.
Price Chart
Executive Summary
GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The trial met its primary objective, showing a sustained clinical complete response rate at 12 months (cCR12), supporting the potential to eliminate or delay chemotherapy, radiation, and surgery. GSK plans to share data with global regulators, including accelerated review in the US, where Jemperli already has Breakthrough Therapy and Fast Track designations.
Key Facts
- AZUR-1 phase II trial (n=154) met primary endpoint: sustained clinical complete response at 12 months (cCR12) in dMMR/MSI-H locally advanced rectal cancer
- Results support potential for Jemperli to become first immunotherapy to eliminate need for chemotherapy, radiation, and surgery in some patients
- Data to be shared with health authorities for regulatory review, including accelerated review in the US
- Jemperli already has Breakthrough Therapy and Fast Track designations from FDA in this setting
- Safety profile consistent with known profile across solid tumors
- Jemperli is not currently approved anywhere for rectal cancer
Financial Impact
Expands Jemperli's addressable market into an estimated 36,500-73,000 annual dMMR/MSI-H rectal cancer patients globally; revenue contribution depends on approval and pricing, but adds to GSK's oncology pipeline value
Risk Factors
- Regulatory approval not guaranteed; FDA may require additional confirmatory data from a randomized trial
- Competition from other PD-1 inhibitors (e.g., Keytruda, Opdivo) already approved in dMMR/MSI-H solid tumors
- Single-arm phase II design may limit regulatory acceptance outside the US
- Commercial uptake depends on pricing, reimbursement, and physician adoption of immunotherapy-only approach
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006614 |
| Document: 0001654954-26-006614-index-headers.html | 0001654954-26-006614 |
| Document: 0001654954-26-006614-index.html | 0001654954-26-006614 |
| Document: 0001654954-26-006614.txt | 0001654954-26-006614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access